AlloSure Lung Assessment and Metagenomics Outcomes Study

Launched by CAREDX · Sep 17, 2021

Keywords

ClinConnect Summary

The AlloSure Lung Assessment and Metagenomics Outcomes Study, also known as the ALAMO trial, is a research study aimed at improving the care of patients who have received a lung transplant. This study is focused on using a special test called AlloSure Lung, which looks for small pieces of DNA in the blood. This test helps doctors detect possible problems like organ rejection or infections caused by bacteria, viruses, or other germs after a transplant.

To be eligible for this study, participants must have received a lung transplant from a deceased donor and be within 90 days of their surgery. They should also be able to understand the study and follow the necessary check-up schedule. Unfortunately, individuals who have had other organ transplants, are pregnant, or currently battling cancer cannot participate. If you join this study, you will receive regular monitoring to help ensure your new lungs are working well and to catch any issues early on. This trial is currently recruiting participants of all ages and genders, aiming to enhance lung transplant care for everyone.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Unilateral or Bilateral, deceased-donor, initial or re-transplant
• • 2. ≤ 90 days post-transplant
• • 3. Ability to understand and provide informed consent and adhere to laboratory surveillance schedule
• • 4. Patients who have LungCare initiated within 30 days of signing the informed consent form
• Exclusion Criteria:
• • 1. Multi-organ transplants
• • 2. Pregnancy
• • 3. Active malignancy